Kangmei Pharmaceutical (600518.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 93.4085 million yuan, a year-on-year increase of 614.01%.

Zhitong Finance APP News, Kangmei Pharmaceutical (600518.SH) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 3.527 billion yuan, a year-on-year decrease of 10.91%; net profit attributable to shareholders of the listed company was 93.4085 million yuan, a year-on-year increase of 614.01%; net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 33.7576 million yuan; basic earnings per share were 0.007 yuan.